PCR Cycle Threshold Arguments and WHO Information Notices
WHO Information Notice 2020/05 instructs PCR users to follow manufacturer IFUs, correlate discordant results clinically, heed prevalence effects on predictive value, and report Ct to clinicians. WHO diagnostic-testing guidance and CDC/FDA assay IFU doors situate RT-PCR as NAT detection with known limits. Adherent “casedemic” readings treat high-Ct/mass testing as manufacturing cases. Contested/L2 documents both without baptism or sneer.
During COVID-19, reverse-transcription polymerase chain reaction (RT-PCR) tests became the primary laboratory tool for detecting SARS-CoV-2 genetic material. Public argument quickly focused on cycle threshold (Ct)—roughly, how many amplification cycles a machine needs before a signal crosses positivity. Official guidance from WHO and CDC/FDA describes Ct as inversely related to viral load, warns that weak positives need clinical context, and tells laboratories to follow manufacturer instructions for use. Adherent “casedemic” readings treat high-Ct positives and mass asymptomatic testing as manufacturing a case epidemic. This page documents both. It does not baptize “PCR invented the pandemic.” It does not sneer at readers who opened the WHO notices.
PublishedSep 23, 2026
What Ct Measures
RT-PCR multiplies target nucleic-acid sequences through repeated thermal cycles. A specimen with abundant target typically crosses the fluorescence threshold early (low Ct). A specimen with scant target—or background noise near the assay’s limit—may cross late (high Ct) or not at all. CDC’s published description of its 2019-nCoV Real-Time RT-PCR Diagnostic Panel, including Emerging Infectious Diseases technical reporting, situates the U.S. public-health assay design and performance claims. FDA hosts the panel’s Instructions for Use as the operational IFU door laboratories were told to follow under emergency authorization. Those documents are the official spine for what the test was authorized to do—not a spreadsheet of every jurisdiction’s reporting policy.
WHO’s September 2020 interim guidance Diagnostic testing for SARS-CoV-2 (WHO/2019-nCoV/laboratory/2020.6) sets laboratory and clinical-context expectations for nucleic-acid testing: specimen quality, assay choice, and careful interpretation of weak positives. The publication door and IRIS PDF are the primary guidance packet adherents and officials both quote when arguing about what a “positive” was supposed to mean in clinical practice. The guidance does not abolish PCR; it situates NAT results inside specimen timing, assay specifics, and clinical information.
In December 2020 WHO issued Information Notice for IVD Users 2020/05 on nucleic-acid testing technologies using PCR for SARS-CoV-2; version 2, dated 13 January 2021 and posted publicly, supersedes the first version. The notice tells laboratory professionals to follow manufacturer IFUs carefully, including any manual adjustment of positivity thresholds; states that Ct needed to detect virus is inversely proportional to viral load; advises that where results do not match clinical presentation, a new specimen should be taken and retested; reminds users that disease prevalence alters predictive value and that false-positive risk rises as prevalence falls; and asks that Ct values be provided in reports to requesting clinicians. That text is the official notice. Adherent media read it as WHO admitting PCR mass-positivity was over-calling infection. WHO and fact-check replies framed it as IFU-compliance and interpretation guidance, not a confession that case counts were fake. Contested clearance records both readings of the same notice.
Related WHO IVD Notice and Adherent “Casedemic” Reading
WHO Information Notice 2021/01 (January 2021) separately asked IVD users to monitor SARS-CoV-2 mutations for assay impact—including unexpected Ct discrepancies between gene targets. It is a neighboring laboratory-risk notice, not the Ct-threshold notice, but adherents sometimes bundle both as proof regulators knew assays were unstable. The “casedemic” adherent method is usually: treat high-Ct or asymptomatic PCR positives as non-infectious detections; treat mass testing plus low prevalence as flooding dashboards with false or clinically meaningless positives; treat WHO 2020/05 language on prevalence and weak positives as institutional admission. Official laboratory guidance replies that PCR detects RNA, that clinical correlation was always required, and that Ct cutoffs are assay- and IFU-specific—not a single global “fake case” dial.
Adherent evidence on this page means: WHO really published IFU/Ct/prevalence language in Notice 2020/05; PCR really reports cycle-based detection rather than a direct infectious-dose meter; jurisdictions really counted laboratory positives into case totals that drove policy. Guidance evidence means: WHO and CDC/FDA really published that weak positives need care, that IFUs govern thresholds, and that predictive value depends on prevalence. Refuse two overclaims. Do not baptize “casedemic / PCR invented COVID cases” as Archive L1 fact. Do not pretend only cranks noticed that Ct and prevalence matter—the agencies put those sentences in public notices for a reason.
Method disputes inside the adherent lane also matter. Some analysts demand a universal Ct cutoff for “infectious”; others treat any high-Ct positive in low prevalence as policy fraud. Official replies emphasize manufacturer IFUs, clinical correlation, and separate culture or antigen tools when infectivity questions dominate. The Archive does not seal that statistics fight as L1. Living laboratory officials and policymakers appear by office and document date.
What the Paper Trail Settles
Settled on WHO/CDC/FDA doors: RT-PCR was a primary SARS-CoV-2 diagnostic NAT technology; Ct relates inversely to detected target quantity; WHO 2020/05 instructs IFU compliance, clinical correlation for discordant results, prevalence caution, and reporting of Ct to clinicians; CDC panel design and IFU are published. Contested by design of this page: whether those notices and Ct debates prove a manufactured case epidemic. Officials describe assay limits and interpretation duties. Adherents describe a casedemic. The paper trail is the WHO notices beside the CDC/FDA assay doors—left under contested / L2 clearance.
As an Amazon Associate we earn from qualifying purchases. Some of these are sold by partners: we may earn a commission if you buy through their links, at no extra cost to you.